Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD05 versus beta-TCP plus autogenous bone for unilateral maxillary sinus floor augmentation
2005-003391-37Phase 2Completed
- Sponsor
- Scil Technology
- Start
- Dec 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of gdf5 in Alveolar bone atrophy (ABL) (2 arms), sponsored by Scil Technology. Primary endpoint: Proportion of newly formed mineralized bone. Started Dec 2005; status: completed.
02
Drugs
gdf5
03
Conditions
Alveolar bone atrophy (ABL)
Beyond the preview
Go deeper on 2005-003391-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003391-37.